Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer – The Results of 20 Years of Follow-up

New England Journal of Medicine

Volumn 332, Issue 14, 1995, Pages 901-906

  Bonadonna, Gianni ^a   Valagussa, Pinuccia ^a   Moliterni, Angela ^a   Zambetti, Milvia ^a   Brambilla, Cristina ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; AMENORRHEA; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, RADICAL; METHOTREXATE; MIDDLE AGED; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 0028909867     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199504063321401     Document Type: Article

References (20)

1. Bonadonna G, Brusamolino E, Valagussa P, Veronesi U Adjuvant study with combination chemotherapy in operable breast cancer. Proc Am Assoc Cancer Res Am Soc Clin Oncol 1975; 16.: 254-254 abstract.
2. Bonadonna G, Brusamolino E, Valagussa P, Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294.: 405-410
3. Fisher B, Carbone P, Economou SG, l-Phenylalanine mustard (L-PAM) in the management of primary breast cancer.: a report of early findings. N Engl J Med 1975; 292.: 117-122
4. Bonadonna G, Valagussa P Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304.: 10-15
5. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53.: 457-481
6. Peto R, Peto J Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 1972; 135.: 185-207
7. Cox D.R. Regression models and life-tables. J R Stat Soc [B] 1972; 34.: 187-220
8. Miller RG. Survival analysis. New York.: John Wiley, 1981.
9. Valagussa P, Brambilla C, Zambetti M, Bonadonna G Salvage treatments in relapsing resectable breast cancer. Recent Results Cancer Res 1989; 115.: 69-76
10. Bonadonna G, Valagussa P, De Palo G. The results of adjuvant chemotherapy are predominantly caused by the hormonal changes such therapy induces. In.: Van Scoy-Mosher MB, ed. Medical oncology.: controversies in cancer treatment. Boston.: G.K. Hall Medical, 1981.:100-109, 112-5.
11. Valagussa P, Moliterni A, Terenziani M, Zambetti M, Bonadonna G Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol 1994; 5.: 803-808
12. Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U The CMF program for operable breast cancer with positive axillary nodes.: updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer 1977; 39.: 2904-2915
13. Wood WC, Budman DR, Korzun AH, Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330.: 1253-1259
14. Moliterni A, Bonadonna G, Valagussa P, Ferrari L, Zambetti M Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 1991; 9.: 1124-1130
15. Bonadonna G, Zambetti M, Valagussa P Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive axillary nodes.: ten-year results. JAMA 1995; 273.: 542-547
16. Fisher B, Brown AM, Dimitrov NV, Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors.: results from National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8.: 1483-1496
17. Goldhirsch A, Gelber RD, Castiglione M The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol 1990; 1.: 183-188
18. Goldhirsch A, Gelber RD, Price KN, Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 1994; 343.: 377-381
19. Henderson IC, Hayes DF, Parker LM, Adjuvant systemic therapy for patients with node-negative tumors. Cancer 1990; 65.: Suppl.: 2132-2147
20. Bonadonna G, Valagussa P, Zucali R, Salvadori B. Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin (in press).